Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer

2008121 citationsJournal Articlebronze Open Access

Authors

Howard L. Kaufman · Columbia University Irving Medical Center

Heinz‐Josef Lenz · University of Southern California

John L. Marshall · Georgetown University Medical Center

Deepti Singh · University of Chicago

Chris Garett · Moffitt Cancer Center

C. Cripps · Ottawa Regional Cancer Foundation

Malcolm J. Moore

Abstract

The combination of ALVAC-CEA/B7.1 vaccine and systemic chemotherapy has an acceptable safety profile in patients with metastatic colorectal cancer. Systemic chemotherapy did not affect the generation of CEA-specific T-cell responses following vaccination.

Topics & Keywords

Immunotherapy and Immune Responses Cancer Immunotherapy and Biomarkers Hepatitis B Virus Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 14, Issue 15, pp. 4843-4849

DOI: 10.1158/1078-0432.ccr-08-0276

Field-Weighted Citation Impact: 2.67